Limits...
[Not Available].

Rolff J, Dorn C, Merk J, Fichtner I - J Oncol (2009)

Bottom Line: The known chemosensitivity to etoposide, carboplatin, gemcitabine, paclitaxel and erlotinib was compared to the protein and mRNA expression of BCRP, LRP, MDR1, and MRP1.All other constitutive mRNA and protein expression levels were not correlated to any drug response and were not significantly influenced by a short term treatment.The present results indicate that the expression levels of MDR proteins and mRNA investigated do not play an important role in the chemoresistance of NSCLC in the in vivo situation.

View Article: PubMed Central - PubMed

Affiliation: Experimental Pharmacology & Oncology GmbH, Robert-Rössle-Street 10, 13122 Berlin, Germany.

ABSTRACT
Tumor cells that are nonsensitive to anticancer drugs frequently have a multidrug resistant (MDR) phenotype. Many studies with cell lines and patient material have been done to investigate the impact of different resistance markers at protein and mRNA level in drug resistance but with contradictory outcome. In the present study, 26 well-characterised patient-derived non-small cell lung cancer xenografts were used. The known chemosensitivity to etoposide, carboplatin, gemcitabine, paclitaxel and erlotinib was compared to the protein and mRNA expression of BCRP, LRP, MDR1, and MRP1. Further, four of these xenografts were short-term treated to analyse possible regulation mechanisms after therapeutic interventions. We found a borderline correlation between the bcrp mRNA expression and the response of xenografts to etoposide. All other constitutive mRNA and protein expression levels were not correlated to any drug response and were not significantly influenced by a short term treatment. The present results indicate that the expression levels of MDR proteins and mRNA investigated do not play an important role in the chemoresistance of NSCLC in the in vivo situation.

No MeSH data available.


Related in: MedlinePlus

mRNA expression of bcrp, lrp, mdr1, and mrp1 after short-term treatment in xenografts 7406, 7433, 7700, and 7747. Treatment was performed for three consecutive days. Three tumor samples per group were taken 24 hours after last treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2696640&req=5

fig1: mRNA expression of bcrp, lrp, mdr1, and mrp1 after short-term treatment in xenografts 7406, 7433, 7700, and 7747. Treatment was performed for three consecutive days. Three tumor samples per group were taken 24 hours after last treatment.

Mentions: In all four xenografts the mRNA of bcrp, lrp, mdr1, and mrp1 could be detected. For one and the same xenograft the mRNA expression was independent of the treatment (Figure 1). The ΔCT values differed in a range of two. No significant up- or down-regulations of the mRNA after treatment with etoposide, carboplatin, gemcitabine, paclitaxel, and erlotinib could be observed.


[Not Available].

Rolff J, Dorn C, Merk J, Fichtner I - J Oncol (2009)

mRNA expression of bcrp, lrp, mdr1, and mrp1 after short-term treatment in xenografts 7406, 7433, 7700, and 7747. Treatment was performed for three consecutive days. Three tumor samples per group were taken 24 hours after last treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2696640&req=5

fig1: mRNA expression of bcrp, lrp, mdr1, and mrp1 after short-term treatment in xenografts 7406, 7433, 7700, and 7747. Treatment was performed for three consecutive days. Three tumor samples per group were taken 24 hours after last treatment.
Mentions: In all four xenografts the mRNA of bcrp, lrp, mdr1, and mrp1 could be detected. For one and the same xenograft the mRNA expression was independent of the treatment (Figure 1). The ΔCT values differed in a range of two. No significant up- or down-regulations of the mRNA after treatment with etoposide, carboplatin, gemcitabine, paclitaxel, and erlotinib could be observed.

Bottom Line: The known chemosensitivity to etoposide, carboplatin, gemcitabine, paclitaxel and erlotinib was compared to the protein and mRNA expression of BCRP, LRP, MDR1, and MRP1.All other constitutive mRNA and protein expression levels were not correlated to any drug response and were not significantly influenced by a short term treatment.The present results indicate that the expression levels of MDR proteins and mRNA investigated do not play an important role in the chemoresistance of NSCLC in the in vivo situation.

View Article: PubMed Central - PubMed

Affiliation: Experimental Pharmacology & Oncology GmbH, Robert-Rössle-Street 10, 13122 Berlin, Germany.

ABSTRACT
Tumor cells that are nonsensitive to anticancer drugs frequently have a multidrug resistant (MDR) phenotype. Many studies with cell lines and patient material have been done to investigate the impact of different resistance markers at protein and mRNA level in drug resistance but with contradictory outcome. In the present study, 26 well-characterised patient-derived non-small cell lung cancer xenografts were used. The known chemosensitivity to etoposide, carboplatin, gemcitabine, paclitaxel and erlotinib was compared to the protein and mRNA expression of BCRP, LRP, MDR1, and MRP1. Further, four of these xenografts were short-term treated to analyse possible regulation mechanisms after therapeutic interventions. We found a borderline correlation between the bcrp mRNA expression and the response of xenografts to etoposide. All other constitutive mRNA and protein expression levels were not correlated to any drug response and were not significantly influenced by a short term treatment. The present results indicate that the expression levels of MDR proteins and mRNA investigated do not play an important role in the chemoresistance of NSCLC in the in vivo situation.

No MeSH data available.


Related in: MedlinePlus